In a major financial and reputational turnaround, South African pharmaceutical giant Aspen Pharmacare has clinched a decisive win in a high-stakes contractual dispute, with the opposing party ordered to pay it €25 million (approximately R500 million). The settlement, announced on Friday, 31 October, brings to a close a saga that has weighed heavily on the company’s performance and investor confidence throughout its 2025 financial year.
The dispute, which stemmed from a manufacturing and technology agreement with a contract manufacturing customer for mRNA products, was a primary contributor to Aspen’s staggering R1 billion loss for the year. The uncertainty had sent shockwaves through the market, causing Aspen’s share price to plummet over 30% when the risks were first disclosed in April 2025.
At the heart of investor anxiety was the potential loss of access to crucial mRNA intellectual property (IP). Aspen, Africa’s largest drugmaker, had invested heavily in betting on mRNA technology as a key growth driver for its manufacturing division. The dispute not only threatened to derail this strategic bet but also triggered a R770 million impairment, as the company faced the possibility of being unable to manufacture mRNA vaccines at all.
Analysts and shareholders had expressed significant frustration over the lack of detailed information, with some questioning the management’s transparency. The concerns were amplified because the manufacturing division, where the problem arose, represented a core part of Aspen’s future growth strategy, supported by its state-of-the-art facilities in Gqeberha and France.
The R500 million settlement, to be paid before 1 December 2025, serves as a substantial financial injection and a vindication for the company. However, Aspen has maintained a veil of confidentiality around the specifics of the case and the identity of the counterparty, citing contractual agreements. While the cash payout is a clear positive, the announcement leaves unanswered questions about the long-term future of Aspen’s mRNA ambitions and whether the resolved dispute fully restores the division’s growth trajectory.
About The Author
